Cure & Sure Biotech

Cure & Sure Biotech is a Chinese biopharmaceutical company specializing in the development of autologous therapeutic cancer vaccines. The company's lead product, Rebys (an autologous heat shock protein-gp96 peptide complex), is the first therapeutic cancer vaccine approved in China for multiple oncology indications, including esophageal, gastric, pancreatic, and liver cancers. Their technology platform utilizes heat shock protein 96 (gp96) extracted from a patient's own tumor tissue to elicit a specific immune response against tumor cells. Cure & Sure Biotech is actively conducting clinical trials to expand the indications for its platform, with ongoing research in glioblastoma and adjuvant settings for gastric cancer.